are employees of Caris Life Sciences. W.M. Korn reports consulting/advisory role from Merrimack and Merck Sharp & Dohme, stock/ownership interests with OncoCyte, has received honoraria from Genentech/Roche and institution-associated funding from Merrimack. E.I. Heath reports consulting/advisory role for Agensys, has received honoraria from Bayer, Dendreon, Sanofi, Seattle Genetics, is on the Speakers' Bureau for Sanofi and research funding from Takai Pharmaceuticals, Seattle Genetics, Agensys, Dendreon and Genentech/Roche.
Diagnosis and treatment of soft tissue sarcoma (STS) is a particularly daunting task, largely due to the profound heterogeneity that characterizes these malignancies. Molecular profiling has emerged as a useful tool to confirm histologic diagnoses and more accurately classify these malignancies. Recent large-scale, multiplatform analyses have begun the work of establishing a more complete understanding of molecular profiling in STS subtypes and to identify new molecular alterations that may guide the development of novel targeted therapies. This review provides a brief and general overview of the role that molecular profiling has in STS, highlighting select sarcoma subtypes that are notable for recent developments. The role of molecular profiling as it relates to diagnostic strategies is discussed, along with ways that molecular profiling may provide guidance for potential therapeutic interventions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.